Repligen | RGEN - Current Assets



Repligen reported $1.03B in Current Assets for its fiscal quarter ending in March of 2025.


Current Assets Change Date
Agilent USD 4.25B 45M Jul/2025
Align Technology USD 2.45B 46.03M Jun/2025
Bio Techne USD 608.3M 18.94M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Bruker USD 2.16B 51.2M Jun/2025
Charles River Laboratories USD 1.47B 36.5M Jun/2025
Danaher USD 11B 1.47B Jun/2025
Dentsply International USD 1.97B 12M Jun/2025
Exact Sciences USD 1.51B 137.52M Jun/2025
General Electric Aerospace USD 37.8B 226M Jun/2025
Henry Schein USD 4.24B 206M Jun/2025
Illumina USD 2.64B 32M Jun/2025
IQVIA Holdings USD 6.35B 434M Jun/2025
Mettler Toledo International USD 1.24B 79.67M Jun/2025
Myriad Genetics USD 287.2M 10.8M Mar/2025
Pfizer USD 43.7B 2.16B Jun/2025
Repligen USD 1.03B 33.58M Mar/2025
Revvity USD 2.24B 81.76M Jun/2025
Standard Biotools USD 506.04M 130.16M Jun/2025
Thermo Fisher Scientific USD 24.58B 1.21B Jun/2025
Waters USD 1.78B 42.24M Jun/2025
West Pharmaceutical Services USD 1.68B 223.4M Jun/2025